Skip to content

Media Hub

Read past presentations, interviews and white paper content

Development of novel NK cell-specific chimeric antigen receptors to improve anti-tumor activity.
Dan S.Kaufman at University of California, School of Medicine


Tumour-mediated NK priming for cancer immunotherapy.
Mark Lowdell at University College London

Mark Lowdell

Engineering NK cells to target the inhibitory solid tumor microenvironment.
Robin Parihar at Baylor College of Medicine

Robin Parihar

NKTR-255: Accessing The Immunotherapeutic Potential of IL-15 for NK Cell Therapies.
Saul Kivimäe at Nektar Therapeutics

Saul Kivimae